Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.35 |
| ▸ | CA1 | P00915 | 9/20 | 0.34 |
| ▸ | CA2 | P00918 | 9/20 | 0.34 |
| ▸ | CA9 | Q16790 | 9/20 | 0.34 |
| ▸ | CA12 | O43570 | 5/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.34 |
| ▸ | CA4 | P22748 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241381 | 1.00 | GPBAR1 (0.40) | GPBAR1PTGS2CHRNA7CA1CA2 | |
| SCHEMBL1390699 | 1.00 | GPBAR1 (0.40) | GPBAR1PTGS2CHRNA7CA1CA2 | |
| SCHEMBL370177 | 1.00 | GPBAR1 (0.40) | GPBAR1PTGS2CHRNA7CA1CA2 | |
| SCHEMBL369724 | 0.97 | GPBAR1 (0.38) | GPBAR1PTGS2CHRNA7CA1CA2 | |
| SCHEMBL369726 | 0.97 | GPBAR1 (0.38) | GPBAR1PTGS2CHRNA7CA1CA2 | |
| SCHEMBL369725 | 0.97 | GPBAR1 (0.38) | GPBAR1PTGS2CHRNA7CA1CA2 | |
| SCHEMBL15949073 | 0.92 | GPBAR1 (0.40) | GPBAR1CYP2D6 | |
| SCHEMBL15949075 | 0.92 | GPBAR1 (0.40) | GPBAR1CYP2D6 | |
| SCHEMBL1389860 | 0.90 | GPBAR1 (0.40) | GPBAR1CHRNA7CA1CA2CA9 | |
| SCHEMBL1390246 | 0.90 | GPBAR1 (0.40) | GPBAR1CHRNA7CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | GPBAR1 1/4885PTGS2 259/4885CHRNA7 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.